Communication on the higher incidence of new cases of ovarian failure observed in premenopausal women treated with Avastin® (Bevacizumab)

Roche, in consultation with HSA is informing healthcare professionals of the higher incidence of new cases of ovarian failure observed in premenopausal women treated with Avastin® (Bevacizumab). It has been observed that there was a higher incidence of new cases of ovarian failure in premenopausal women treated with Avastin® + mFOLFOX6 as compared in FOLFOX6 alone, in HSABP C-08, a phase III trial in adjuvant treatment of patients with colon cancer. The causal role of Avastin® cannot be ruled out in these cases. Fertility preservation strategies should be discussed with women of child-bering potential prior to starting treatment with Avastin®. The package insert of Avastin® will be updated to reflect this latest finding from the study NSABP C-08.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.